Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)

Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M

research

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)

Authors: M Bianco
F Buzzi
R Cioffi
P Comella
G De Cataldis
G Filippelli
G Frasci
A Gambardella
M Ghiani
L Maiorino
S Mancarella
B Massidda
P Masullo
V Milia
D Natale
S Palmeri
C Putzu
M Roselli
Publication date: 1 February 2007
Publisher: Oxford University Press
Doi

Abstract

Triplet regimens were occasionally reported to produce a higher response rate (RR) than doublets in locally advanced or metastatic non-small-cell lung cancer (NSCLC). This trial was conducted to assess (i) whether the addition of cisplatin (CDDP) to either gemcitabine (GEM) and vinorelbine (VNR) or GEM and paclitaxel (PTX) significantly prolongs overall survival (OS) and (ii) to compare the toxicity of PTX-containing and VNR-containing combinations